Harry Raftopoulos

Company: Eikon Therapeutics

Job title: Senior Vice President, Clinical Research, Head of Oncology

Seminars:

Panel Discussion: What’s Next for DDR Therapeutics? Evaluating Next-Gen PARP Inhibitors, Novel Targets, & the Future of Clinical Validation 4:15 pm

How are biopharma validating novel DDR targets, and what role will next-gen PARP inhibitors play in the evolving landscape of DDR therapeutics? What preclinical frameworks are currently in use for DDR inhibitors, and how can they be enhanced to better predict clinical success and viability? As we look to the future, could expanding data access—such…Read more

day: Day Two